Title of article
Prevalence and Risk Factors for Non-Vertebral Fractures in Patients Receiving Oral Glucocorticoids
Author/Authors
Manuel, Sosa-HenrIquez Spanish Society for Investigation of Osteoporosis and Bone Metabolic Diseases (SEIOMM), Spain , Manuel, Sosa-HenrIquez University of Las Palmas de Gran Canaria, Spain , Maria Jesus, Gomez de Tejada-Romero Spanish Society for Investigation of Osteoporosis and Bone Metabolic Diseases (SEIOMM), Spain , Pedro, Saavedra-Santana University of Las Palmas de Gran Canaria, Spain , Jose Antonio, Blazquez-Cabrera Spanish Society of Internal Medicine (SEMI), Spain , Jesús Alberto, Garcia-Vadillo Spanish Society of Rheumatology (SER), Spain , Carmen, Valdes-Llorca Spanish Society of General Practitioners (SEMERGEN), Spain , Manuel, Diaz-Curiel Spanish Foundation for Osteoporosis and Metabolic Diseases (FHOEMO), Spain , Manuel, Munoz-Torres Spanish Society of Endocrinology and Metabolism (SEEN), Spain , Maria Elena, Martinez-Rodriguez Spanish Society of Physical Medicine and Rehabilitation (SERMEF), Spain , Carmen, Navarro-Ceballos Spanish Society of Geriatrics and Gerontology (SEGG), Spain , Jose, Sanfelix-Genoves Spanish Society of General Practitioners (SEMFyC), Spain , Maria Jesus, Cancelo-Hidalgo Spanish Association for Study of Menopause (AEEM), Spain , Pedro, Carpintero-Benitez Spanish Society for Study of Osteoporotic Fractures (SEFRAOS), Spain , Manuel, Mesa-Ramos Spanish Society of Orthopaedic Surgeons (SECOT), Spain , Santiago, Palacios-Gil Antunano International Society of Osteoporosis and Bone Mineral Metabolism (SIBOMM), Spain , Spanish and International Scientific
From page
480
To page
485
Abstract
Introduction: Glucocorticoids taken orally increase the risk of fractures. It has been noted that a dose as low as 2.5 mg/day increases the risk of vertebral fracture. What is less clear is the possible influence of other risk factors for osteoporosis on the presence of non-vertebral fractures in patients taking glucocorticoids. Patients and Methods: A cross-sectional study, performed on 513 men and women from Spain, who were taking at least 7.5 mg/day of oral prednisone for a minimum of 3 months. A questionnaire was developed, through which information on risk factors was collected. Results: 28.3% of the patients who were taking glucocorticoids at a daily oral dose of 7.5 mg/ day for a minimum of 3 months had suffered at least one non-vertebral fracture. The risk increased with age, the number of months the glucocorticoids had been taken, the presence of falls in the last year and, above all, with a maternal history of hip fracture. Conclusions: In patients taking oral glucocorticoids for over 3 months at doses higher than 7.5 mg/day of prednisone or equivalent, the prevalence of non-vertebral fractures was 28.3%. Some risk factors associated with the presence of these fractures were identified. The duration of glucocorticoid use appears to be more strongly related to the presence of non-verte- bral fractures than the daily dose.
Keywords
Adrenal Cortex Hormones Osteoporosis
Journal title
International Journal of Endocrinology and Metabolism
Journal title
International Journal of Endocrinology and Metabolism
Record number
2562673
Link To Document